Bausch + Lomb Corp
NYSE:BLCO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its 3-Year Average (16.8), the stock would be worth $15.92 (1% downside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 16.9 | $16.05 |
0%
|
| 3-Year Average | 16.8 | $15.92 |
-1%
|
| 5-Year Average | 16.4 | $15.56 |
-3%
|
| Industry Average | 13.4 | $12.7 |
-21%
|
| Country Average | 10.2 | $9.63 |
-40%
|
Forward EV/EBITDA
Today’s price vs future ebitda
| Today's Enterprise Value | EBITDA | Forward EV/EBITDA | ||
|---|---|---|---|---|
|
$11B
|
/ |
Jan 2026
$609m
|
= |
|
|
$11B
|
/ |
Dec 2026
$1B
|
= |
|
|
$11B
|
/ |
Dec 2027
$1.2B
|
= |
|
|
$11B
|
/ |
Dec 2028
$1.3B
|
= |
|
Forward EV/EBITDA shows whether today’s EV/EBITDA still looks high or low once future ebitda are taken into account.
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| CA |
|
Bausch + Lomb Corp
NYSE:BLCO
|
5.7B USD | 16.9 | -15.7 | |
| US |
M
|
Medline Inc
NASDAQ:MDLN
|
62B USD | 0 | 0 | |
| JP |
|
Hoya Corp
TSE:7741
|
9.7T JPY | 28.1 | 38.7 | |
| CH |
|
Alcon AG
SIX:ALC
|
30.1B CHF | 14.5 | 37.7 | |
| DK |
|
Coloplast A/S
CSE:COLO B
|
96.5B DKK | 12.7 | 24 | |
| US |
|
Align Technology Inc
NASDAQ:ALGN
|
14B USD | 14.9 | 34.1 | |
| UK |
|
ConvaTec Group PLC
LSE:CTEC
|
4.5B GBP | 11.9 | 34.3 | |
| KR |
H
|
HLB Inc
KOSDAQ:028300
|
8T KRW | -81.4 | -36.4 | |
| JP |
A
|
Asahi Intecc Co Ltd
TSE:7747
|
868.9B JPY | 23.2 | 49.1 | |
| US |
|
Lantheus Holdings Inc
NASDAQ:LNTH
|
5.4B USD | 14.7 | 22.9 | |
| CN |
|
Intco Medical Technology Co Ltd
SZSE:300677
|
36.4B CNY | 31.5 | 21.4 |
Market Distribution
| Min | 0 |
| 30th Percentile | 7 |
| Median | 10.2 |
| 70th Percentile | 14.5 |
| Max | 13 731.1 |
Other Multiples
Bausch + Lomb Corp
Glance View
Founded in 1853, Bausch + Lomb Corp. began as a small optical goods store in Rochester, New York, eventually blossoming into a multinational eye health business. Over its long history, the company has established itself as a cornerstone in the realm of vision care, leveraging its deep expertise to innovate and expand its product offerings. Today, Bausch + Lomb operates through three primary business segments: Vision Care, Ophthalmic Pharmaceuticals, and Surgical. In the Vision Care segment, it provides contact lenses, lens care products, and other related items, making it a trusted choice for consumers around the globe. The Ophthalmic Pharmaceuticals division addresses a broad spectrum of eye health needs, producing prescription and over-the-counter pharmaceuticals that target various eye conditions. Meanwhile, the Surgical segment offers a suite of ophthalmic surgical devices, designed for procedures ranging from cataract extraction to vitreoretinal surgery. Bausch + Lomb generates revenue through a mix of consumer products and medical equipment. Their extensive contact lens product line caters to diverse needs – from daily disposables to specialized lenses for specific eye conditions, thereby capturing a significant portion of the eye care market. The company's pharmaceuticals and surgical tools not only complement its vision care products but also tap into the lucrative medical market, providing solutions for both medical professionals and their patients. By maintaining a robust portfolio that spans consumer goods and professional-grade equipment, Bausch + Lomb effectively positions itself as both a retail and medical partner, ensuring steady revenue streams from a global customer base. With a blend of research-driven innovation and strategic market positioning, Bausch + Lomb continues to cement its legacy as a leader in eye health.